Among the current ocular hypotension medications employed in treating open-angle glaucoma and ocular hypertension, prostaglandin analogues are the most potent. These include Bimatoprost and Latanoprost. In the United States, latanoprost has been commercially available since 1996. These pharmaceutical agents’ precise mode of action to lower intraocular pressure is still not understood; they are believed to act by increasing aqueous humour outflow via the trabecular route and the uveoscleral pathway.
The goal is to reduce intraocular pressure (IOP) to protect against damage to optic nerves and progressive loss of vision. Once-daily prostaglandin administration has become the first-line treatment approach for many patients with glaucoma or ocular hypertension. Both ophthalmic solutions reduce IOP effectively and safely and generally well tolerated.
Latanoprost eye drops and Bimatoprost 0.03% have shown to appear extremely effective in lowering IOP than any other agents. Monotherapy is usually chosen over the use of multiple IOP lowering medications to gain control over raised IOP. A single therapy minimizes drug exposure and the possibility of ocular and systematic adverse reactions. Treatment with a single medication also avoids the inconvenience of using multiple eye drops, which can be a barrier to treatment adherence.
Among these prostaglandin medications, the prostamide Bimatoprost 0.03% has an excellent IOP lowering efficacy profile. It has been shown to achieve greater IOP lowering effects in clinical trials when compared with latanoprost. The most frequent adverse reaction of this 0.03% ophthalmic reparation is conjunctival hyperemia. However, there is extensive documentation concerning the effectiveness of these two prostaglandin analogues. The studies have shown no clinically significant differences in the IOP lowering ability of these medications. However, investigators suggest that it may be more effective than latanoprost in reducing IOP levels. Compared to latanoprost, Bimatoprost has been shown to have substantially higher rates of ocular side effects.
Latanoprost belongs to a class of drugs known as prostaglandin analogues. The class of medication acts by increasing the natural outflow of fluid from inside the eye into the bloodstream. Latanoprost is a prescription treatment for intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It may be given to reduce intraocular pressure in patients with chronic angle-closure glaucoma who underwent laser surgery. It is an effective remedy for conditions like open-angle glaucoma and ocular hypertension in adults. Both eye problems are associated with an increase in the pressure within your eye, eventually affecting the vision. The eye medication is useful in treating increased eye pressure and glaucoma in all ages of children and babies. The ophthalmic preparation should not be given to people with known hypersensitivity to be benzalkonium chloride or any other ingredients of the eye drop. One drop in the affected eye once daily in the evening is sufficient. Do not exceed the once-daily dose because it has been shown in the clinical trials that regular administration may cause a significant reduction in the IOP lowering effect.
Since the introduction of latanoprost in 1996 as an ocular hypertensive agent for the treatment of glaucoma, eyelash growth has been reported as a regular phenomenon associated with ophthalmic prostaglandin.
One ml of solution contains 0.3 ml bimatoprost careprost and is specially designed pharmacologically to reduce IOP for the treatment of glaucoma. It is quite similar to the prostaglandin analogue, which is considered an effective ocular hypotensive agent. Compared to latanoprost in clinical studies, this pharmaceutical agent was more effective as an eyelash growth solution. It was approved by the US food and drug administration (FDA) for increasing eyelash length, thickness, and darkness in patients with hypertrichosis of eyelashes.
The purpose of this information guide is to prospectively evaluate intraocular pressure reduction (IOP) reduction efficacy and safety between Bimatoprost and latanoprost. Data supports studies indicating that bimatoprost 0.03% provides greater IOP reduction than latanoprost. Reports suggest that eight weeks of Bimatoprost eye drop provided an additional mean IOP reduction in patients. Many patients who do not reach their target IOP on latanoprost can achieve additional IOP lowering and maintain monotherapy by replacing latanoprost with Bimatoprost eye drop.